Lexaria Bioscience
LEXX
20 hedge funds and large institutions have $1.49M invested in Lexaria Bioscience in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
33% more funds holding
Funds holding: 15 → 20 (+5)
10.26% less ownership
Funds ownership: 21.9% → 11.63% (-10%)
16% less capital invested
Capital invested by funds: $1.77M → $1.49M (-$276K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$330K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$77.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$38.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$889K |
| 2 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$41.6K |
| 3 |
Renaissance Technologies
New York
|
-$13K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$10.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.25K |
LEXX Hedge Fund Activity: Q4 2023 in Review
20 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q4 2023, worth a combined $1.49M — down 16% from $1.77M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LEXX positions and 3 closed out — a net gain of 5 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $330K. The largest seller was Armistice Capital, exiting entirely with an estimated $889K sold.
- 20 institutional investors held Lexaria Bioscience (LEXX) as of Q4 2023, up from 15 in Q3 2023.
- Funds reported $1.49M of Lexaria Bioscience stock for Q4 2023, down 16% quarter-over-quarter.
- 8 funds opened new Lexaria Bioscience positions in Q4 2023 and 3 closed out, a net change of +5 holders.
- The largest Lexaria Bioscience buyer in Q4 2023 was Cowen and Company, an estimated $330K added.
- The largest Lexaria Bioscience seller in Q4 2023 was Armistice Capital, an estimated $889K sold.
Based on aggregated 13F filings for Q4 2023.